Enliven Therapeutics Inc(ELVN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.67 | Insider Own | 16.82% | Shs Outstand | 73.3M | Perf Week | 5.92% |
| Market Cap | 3.20B | Forward P/E | - | EPS next Y | -22.29% | Insider Trans | -10.16% | Shs Float | 61.0M | Perf Month | -5.04% |
| Enterprise Value | 2.31B | PEG | - | EPS next Q | -0.45 | Inst Own | 97.91% | Short Float | 15.31% | Perf Quarter | -17.52% |
| Income | -0.11B | P/S | - | EPS this Y | -1.48% | Inst Trans | 40.54% | Short Ratio | 7.18 | Perf Half Y | 1.65% |
| Sales | 0.00B | P/B | 3.58 | EPS next 5Y | -15.63% | ROA | -14.98% | Short Interest | 9.33M | Perf YTD | 183.7% |
| Book/sh | 12.22 | P/C | 3.58 | EPS past 3/5Y | 46.65% 33.56% | ROE | -15.31% | 52W High | -29.89% ($62.32) | Perf Year | 104.16% |
| Cash/sh | 12.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -11.82% | 52W Low | 195.5% ($14.78) | Perf 3Y | 297.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.62% | Gross Margin | - | Volatility(W/M) | 4.09% 4.35% | Perf 5Y | 205.95% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.95 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 64.07 | EPS Q/Q | -0.97% | Profit Margin | - | RSI (14) | 49.46 | Recom | 1.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 64.07 | Sales Q/Q | - | SMA20 | 4.46% ($41.82) | Beta | 0.34 | Target Price | $73.92 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/5 | SMA50 | -11.89% ($49.59) | Rel Volume | 2.54 | Prev Close | $41.49 |
| Employees | 60 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -26.55% - | SMA200 | 2.93% ($42.45) | Avg Volume(3M) | 1.30M | Price | $43.69 |
| IPO | 2020/3/12 | Option/Short | Yes/Yes | Trades | 11360 | Volume | 3,308,365 | Change | 5.3% |
A U.S. clinical-stage biotech company developing precision oncology therapeutics. It develops precision anti-cancer drugs that target specific signaling pathways in cancer cells and has candidates aimed at hematologic cancers such as leukemia as well as solid tumors. With differentiated mechanisms of action and a late-stage clinical lead candidate, it is a precision oncology biotech entering areas of high unmet need in cancer treatment.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded more than usual. That is 254% of its average volume.
ELVN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -1.5% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +205.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 97.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #69 of 594 in the industry
Based on market cap of $3B.
PBLS#67 Parabilis Medicines Inc $3B PER - 
IDYA#68 Ideaya Biosciences Inc $3B PER - ELVN#69 Enliven Therapeutics Inc $3B PER - 
VKTX#70 Viking Therapeutics Inc $3B PER - 
DYN#71 Dyne Therapeutics Inc $3B PER - 
FAQ
What kind of company is ELVN?
ELVN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ELVN?
The market cap of ELVN is approximately $3.2B, ranking 1,709 within its sector.
What is the 52-week high and low for ELVN?
ELVN has recorded a 52-week high of $62.32 and a low of $14.78.
